Literature DB >> 14716830

Stable expression of human cytochrome P450 2D6*10 in HepG2 cells.

Jian Zhuge1, Ying-Nian Yu, Xiao-Dan Wu.   

Abstract

AIM: Over 90% of drugs are metabolized by the cytochrome P-450 (CYP) family of liver isoenzymes. The most important enzymes are CYP1A2, 3A4, 2C9/19, 2D6 and 2E1. Although CYP2D6 accounts for <2% of the total CYP liver enzyme content, it mediates metabolism in almost 25% of drugs. In order to study its enzymatic activity for drug metabolism, its cDNA was cloned and a HepG2 cell line stably expressing CYP2D6 was established.
METHODS: Human CYP2D6 cDNA was amplified with reverse transcription-polymerase chain reaction (RT-PCR) from total RNA extracted from human liver tissue and cloned into pGEM-T vector. cDNA segment was identified by DNA sequencing and subcloned into a mammalian expression vector pREP9. A cell line was established by transfecting the recombinant plasmid of pREP9-CYP2D6 to hepatoma HepG2 cells. Expression of mRNA was validated by RT-PCR. Enzyme activity of catalyzing dextromethorphan O-demethylation in postmitochondrial supernatant (S9) fraction of the cells was determined by high performance liquid chromatography (HPLC).
RESULTS: The cloned cDNA had 4 base differences, e.g. 100 C-T, 336 T-C, 408 C-G and 1 457 G-C, which resulted in P34S, and S486T amino acid substitutions, and two samesense mutations were 112 F and 136 V compared with that reported by Kimura et al (GenBank accession number: M33388). P34S and S486T amino acid substitutions were the characteristics of CYP2D6*10 allele. The relative activity of S9 fraction of HepG2-CYP2D6*10 metabolized detromethorphan O-demethylation was found to be 2.31 +/- 0.19 nmol/min(-1)/mg(-1) S9 protein (n=3), but was undetectable in parental HepG2 cells.
CONCLUSION: cDNA of human CYP2D6*10 can be successfully cloned. A cell line, HepG2-CYP2D6*10, expressing CYP2D6*10 mRNA and having metabolic activity, has been established.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716830      PMCID: PMC4717011          DOI: 10.3748/wjg.v10.i2.234

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.

Authors:  Katsunori Nakamura; Noritaka Ariyoshi; Tsuyoshi Yokoi; Satoru Ohgiya; Michihiro Chida; Kazuo Nagashima; Kazuaki Inoue; Takao Kodama; Noriaki Shimada; Tetsuya Kamataki
Journal:  Biochem Biophys Res Commun       Date:  2002-05-10       Impact factor: 3.575

Review 2.  Development and validation of alternative metabolic systems for mutagenicity testing in short-term assays.

Authors:  J Rueff; C Chiapella; J K Chipman; F Darroudi; I D Silva; M Duverger-van Bogaert; E Fonti; H R Glatt; P Isern; A Laires; A Léonard; M Llagostera; P Mossesso; A T Natarajan; F Palitti; A S Rodrigues; A Schinoppi; G Turchi; G Werle-Schneider
Journal:  Mutat Res       Date:  1996-06-12       Impact factor: 2.433

3.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Authors:  T Kronbach; D Mathys; M Umeno; F J Gonzalez; U A Meyer
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

4.  Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population.

Authors:  M Garcia-Barceló; L Y Chow; H F Chiu; Y K Wing; D T Lee; K L Lam; M M Waye
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

Review 5.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

6.  Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.

Authors:  Wei-Min Cai; Jun Xu; Bing Chen; Fu-Min Zhang; Yuan-Zhu Huang; Yin-Di Zhang
Journal:  Acta Pharmacol Sin       Date:  2002-11       Impact factor: 6.150

7.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

Authors:  T Fukuda; I Yamamoto; Y Nishida; Q Zhou; M Ohno; K Takada; J Azuma
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

8.  Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells.

Authors:  Ge-Jian Zhu; Ying-Nian Yu; Xin Li; Yu-Li Qian
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

9.  Cloning of UGT1A9 cDNA from liver tissues and its expression in CHL cells.

Authors:  X Li; Y N Yu; G J Zhu; Y L Qian
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

10.  Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.

Authors:  Q Y Yue; Z H Zhong; G Tybring; P Dalén; M L Dahl; L Bertilsson; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1998-10       Impact factor: 6.875

View more
  2 in total

1.  Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6(*)1 and CYP2D6(*)10 using cell-based models in vitro.

Authors:  Qiang Qu; Jian Qu; Lu Han; Min Zhan; Lan-xiang Wu; Yi-wen Zhang; Wei Zhang; Hong-hao Zhou
Journal:  Acta Pharmacol Sin       Date:  2014-05       Impact factor: 6.150

2.  Effects of Flos carthami on CYP2D6 and on the Pharmacokinetics of Metoprolol in Rats.

Authors:  Gaofeng Liu; Yan Liu; Rui Liu; Feng Dong; Zhiren Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2010-11-28       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.